ArticlePloS one2025
iProtDNA-SMOTE: Enhancing protein-DNA binding sites prediction through imbalanced graph neural networks.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-DNA interactions play a crucial role in cellular biology, essential for maintaining life processes and regulating cellular functions. We propose a method called iProtDNA-SMOTE, which utilizes non-equilibrium graph neural networks along with pre-trained protein language models to predict DNA binding residues. This approach effectively addresses the class imbalance issue in predicting protein-DNA binding sites by leveraging unbalanced graph data, thus enhancing model's generalization and specificity. We trained the model on two datasets, TR646 and TR573, and conducted a series of experiments to evaluate its performance. The model achieved AUC values of 0.850, 0.896, and 0.858 on the independent test datasets TE46, TE129, and TE181, respectively. These results indicate that iProtDNA-SMOTE outperforms existing methods in terms of accuracy and generalization for predicting DNA binding sites, offering reliable and effective predictions to minimize errors. The model has been thoroughly validated for its ability to predict protein-DNA binding sites with high reliability and precision. For the convenience of the scientific community, the benchmark datasets and codes are publicly available at https://github.com/primrosehry/iProtDNA-SMOTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.